Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: genetics – Page 436

The claustrum coordinates cortical slow-wave activity

During sleep and awake rest, the neocortex generates large-scale slow-wave (SW) activity. Here, we report that the claustrum coordinates neocortical SW generation. We established a transgenic mouse line that enabled the genetic interrogation of a subpopulation of claustral glutamatergic neurons. These neurons received inputs from and sent outputs to widespread neocortical areas. The claustral neuronal firings mostly correlated with cortical SW activity. In vitro optogenetic stimulation of the claustrum induced excitatory postsynaptic responses in most neocortical neurons, but elicited action potentials primarily in inhibitory interneurons. In vivo optogenetic stimulation induced a synchronized down-state featuring prolonged silencing of neural activity in all layers of many cortical areas, followed by a down-to-up state transition. In contrast, genetic ablation of claustral neurons attenuated SW activity in the frontal cortex. These results demonstrate a crucial role of claustral neurons in synchronizing inhibitory interneurons across wide cortical areas for the spatiotemporal coordination of SW activity.

Tiny RNA that should attack coronavirus diminish with age, disease

A group of tiny RNA that should attack the virus causing COVID-19 when it tries to infect the body are diminished with age and chronic health problems, a decrease that likely helps explain why older individuals and those with preexisting medical conditions are vulnerable populations, investigators report.

MicroRNAs play a big role in our body in controlling gene expression, and also are a front line when viruses invade, latching onto and cutting the RNA, the genetic material of the , says Dr. Sadanand Fulzele, aging researcher in the Department of Medicine and Center for Healthy Aging at the Medical College of Georgia at Augusta University.

But with age and some chronic medical conditions, the attacking microRNA numbers dwindle, reducing our ability to respond to viruses, says Dr. Carlos M. Isales, co-director of the MCG Center for Healthy Aging and chief of the MCG Division of Endocrinology, Diabetes and Metabolism.

CRISPR plants: new non-GMO method to edit plants

An NC State researcher has developed a new way to get CRISPR/Cas9 into plant cells without inserting foreign DNA. This allows for precise genetic deletions or replacements, without inserting foreign DNA. Therefore, the end product is not a genetically modified organism, or GMO.

CRISPR/Cas9 is a tool that can be used to precisely cut and remove or replace a specific genetic sequence. The Cas9 serves as a pair of molecular scissors, guided to the specific genetic target by an easily swapped RNA guide. Basically, it seeks out a specific genetic sequence and, when it finds that sequence, cuts it out. Once the target DNA is snipped, it can be deleted or replaced.

The CRISPR/Cas9 system has tremendous potential for improving crops by changing their genetic code. That does not necessarily mean inserting foreign DNA, but the systems used to deliver CRISPR/Cas9 into a plant’s cells often do, which means the relevant crop is a GMOs undergo through a rigorous evaluation process and many consumers prefer non-GMO products.

Epigenetic changes during aging and their reprogramming potential

If you are interested in age reversal, and you haven’t read Dr David Sinclair (Harvard Medical School) yet, then I’d recommend this research paper.

“Excitingly, new studies show that age-related epigenetic changes can be reversed with interventions such as cyclic expression of the Yamanaka reprogramming factors. This review presents a summary of epigenetic changes that occur in aging, highlights studies indicating that epigenetic changes may contribute to the aging process and outlines the current state of research into interventions to reprogram age-related epigenetic changes.”

The aging process results in significant epigenetic changes at all levels of chromatin and DNA organization. These include reduced global heterochromatin, nucleosome remodeling and loss, changes in histone marks, global DNA hypomethylation with CpG island hypermethylation, and the relocalization of chromatin modifying factors. Exactly how and why these changes occur is not fully understood, but evidence that these epigenetic changes affect longevity and may cause aging, is growing. Excitingly, new studies show that age-related epigenetic changes can be reversed with interventions such as cyclic expression of the Yamanaka reprogramming factors. This review presents a summary of epigenetic changes that occur in aging, highlights studies indicating that epigenetic changes may contribute to the aging process and outlines the current state of research into interventions to reprogram age-related epigenetic changes.

The term “epigenetics” is thrown around a lot. Originally, it was coined to describe heritable changes that were non-mendelian, but use of the term has evolved. These days, “epigenetics” more generally refers to all non-genomic information storage in cells including gene networks, chromatin structure and post-translational modifications to histones. With aging, there are distinct changes across the epigenome from DNA modifications to alterations in global chromatin organization. But key questions remain unanswered: How and why do these changes occur? Do these changes drive disease and aging? Are they reversible?

Genomic organization is determined by the complex structure of chromatin ( Figure 1 ). The basic unit of chromatin is the nucleosome, which is made up of 147 DNA base pairs wrapped around an octamer of histone proteins. This octamer usually comprises two copies each of H2A, H2B, H3 and H4 (Luger et al. 1997; Hansen 2002). Within nucleosomes, both histones and the DNA itself are subject to a range of chemical modifications that affect the chromatin structure and ultimately the expression of genes. Chromatin falls into one of two major subtypes: euchromatin, in which the chromatin is open and transcriptionally active and heterochromatin, in which the chromatin is tightly closed and transcriptionally silent (Wallrath 1998; Grewal and Moazed 2003). Regulating the epigenetic network are factors that modify chromatin including DNA- and histone-modifying enzymes, transcription factors, and the more recently identified noncoding RNAs (ncRNAs).

Blood Factors Reverse Epigenetic Age

Crucially, plasma treatment of the old rats reduced the epigenetic ages of blood, liver and heart by a very large and significant margin, to levels that are comparable with the young rats. According to the six epigenetic clocks, the plasma fraction treatment rejuvenated liver by 73.4%, blood by 52%, heart by 52%, and hypothalamus by 11%. The rejuvenation effects are even more pronounced if we use the final versions of our epigenetic clocks: liver 75%, blood 66%, heart 57%, hypothalamus 19%. According to the final version of the epigenetic clocks, the average rejuvenation across four tissues was 54.2%.

Researchers have demonstrated that epigenetic age can be halved in rats by using signals commonly found in the blood.

Epigenetic changes

One of the proposed reasons we age are the changes to gene expression that our cells experience as we get older; these are commonly called epigenetic alterations. These alterations harm the fundamental functions of our cells and can increase the risk of cancer and other age-related diseases.

Stem cell treatment in the UAE sees ‘favorable’ outcomes for coronavirus patients

Stem Cell Neurotherapy sends therapeutic messages, e.g., “your stem cells are transforming into new cells for the lungs, liver, and kidneys” to the DNA inside the nucleus of stem cells. Inside the nucleus, the DNA receives the message and transmits it to the RNA, which translates the message into genetic code.

The genes inside the stem cells transmit the coded message to the proteins, which are converted by the mitochondria into ATP, which provides the energy for the coded message to transform the stem cells into a new set of lung cells, as well as new cells for the kidneys and liver.

These new cells in the lungs, kidneys, and liver will replace the cells that were infected by the COVID-19 virus. This results in the elimination of the coughing, fever, headaches, diarrhea, and breathing problems.

“If all … went well and it worked well, then I would propose … three months’ time,” she said, when asked how quickly the treatment, which was developed by doctors and researchers at the Abu Dhabi Stem Cell Center, could reach the market.

To date, there are no known vaccines or specific antiviral medicines against Covid-19. U.S. health officials say developing a vaccine will take at least 12 to 18 months.

The UAE has 14,163 cases and 126 deaths due to the coronavirus, based on data from Johns Hopkins University.

Continue reading “Stem cell treatment in the UAE sees ‘favorable’ outcomes for coronavirus patients” | >

Stem cell treatment for coronavirus symptoms being trialed in the UAE

We repurposed some tools from the Stem Cell Therapy for Cancer/Brain Tumor. Those tools are T-Cells, B-Cells, and Natural Killer Cells. Instead of programming those cancer killing cells to attack cancer cells, we have programmed them to seek out, identify, attack, and destroy all the Coronavirus cells in the entire body.

Stem Cell Neurotherapy sends therapeutic messages, e.g., “your stem cells are transforming into new cells for the lungs, liver, and kidneys” to the DNA inside the nucleus of stem cells. Inside the nucleus, the DNA receives the message and transmits it to the RNA, which translates the message into genetic code.

The genes inside the stem cells transmit the coded message to the proteins, which are converted by the mitochondria into ATP, which provides the energy for the coded message to transform the stem cells into a new set of lung cells, as well as new cells for the kidneys and liver.

Reversing age: dual species measurement of epigenetic age with a single clock

Young blood plasma is known to confer beneficial effects on various organs in mice. However, it was not known whether young plasma rejuvenates cells and tissues at the epigenetic level; whether it alters the epigenetic clock, which is a highly-accurate molecular biomarker of aging. To address this question, we developed and validated six different epigenetic clocks for rat tissues that are based on DNA methylation values derived from n=593 tissue samples. As indicated by their respective names, the rat pan-tissue clock can be applied to DNA methylation profiles from all rat tissues, while the rat brain-, liver-, and blood clocks apply to the corresponding tissue types. We also developed two epigenetic clocks that apply to both human and rat tissues by adding n=850 human tissue samples to the training data. We employed these six clocks to investigate the rejuvenation effects of a plasma fraction treatment in different rat tissues. The treatment more than halved the epigenetic ages of blood, heart, and liver tissue. A less pronounced, but statistically significant, rejuvenation effect could be observed in the hypothalamus. The treatment was accompanied by progressive improvement in the function of these organs as ascertained through numerous biochemical/physiological biomarkers and behavioral responses to assess cognitive functions. Cellular senescence, which is not associated with epigenetic aging, was also considerably reduced in vital organs. Overall, this study demonstrates that a plasma-derived treatment markedly reverses aging according to epigenetic clocks and benchmark biomarkers of aging.

Several authors are founders, owners, employees (Harold Katcher and Akshay Sanghavi) or consultants of Nugenics Research (Steve Horvath and Agnivesh Shrivastava) which plans to commercialize the “Elixir” treatment. Other authors (Kavita Singh, Shraddha Khairnar) received financial support from Nugenics Research. The other authors do not have conflict of interest.

CRISPR Used Inside a Person’s Body for the First Time Ever

Doctors at the Casey Eye Institute at Oregon Health & Science University in Portland have announced the first-ever use of the revolutionary gene editing tool, CRISPR, inside of a person’s body. The tool was used to modify the genes responsible for a particular form of inherited blindness, and those responsible for the pioneering effort say there is real potential here to not only restore the patient’s vision, but open up a new line of medicines specifically used to target and alter DNA.

In an Associated Press report, which comes via NBC, the companies that make the treatment used in the procedure, including Cambridge, Massachusetts-based Editas Medicine and Dublin-based Allergan, highlighted the possibilities moving forward if the trial proves to be successful. Charles Albright, chief scientific officer at Editas, said that “We literally have the potential to take people who are essentially blind and make them see.”

Scientists at the OHSU @CaseyEye Institute have injected a harmless virus containing #CRISPR gene-editing instructions inside the retinal cells of a patient with a rare form of genetic blindness. @NPR @RobSteinNews https://n.pr/3ar3l3M— OHSU News (@OHSUNews) March 6, 2020

/* */